Dr. Yeo Khung Keong, Dr. Wiwun Tungsubutra, Prof. Peter Collins, 20170831100001
Agents such as beta-blockers and calcium antagonists have been the cornerstone of treatment for stable angina for some time. However, new options are emerging for patients who remain inadequately controlled on conventional therapies. At a recent Menarini-sponsored symposium held during the APSC Congress 2017 in Singapore, three experts discussed the current treatment landscape, as well as changing paradigms and new effective options for patients with symptomatic angina.
Results from a survey presented at the 2017 Asia Pacific Society of Cardiology Congress indicate that 98% of respondents involved in managing patients with hypertension in Singapore recommend home blood pressure monitoring (HBPM) to patients with hypertension. However, a number of barriers remain to the effective use of out-of-office blood pressure (BP) monitoring.
Prof. Peter Collins, Prof. Giuseppe Mancia, Prof. Carolyn Lam, Dr. Choo Gim Hooi, 20170712103633
Coronary artery disease (CAD) is the leading cause of death worldwide
and is expected to remain so for the foreseeable future due to both the
ageing population and the increasing prevalence of risk factors such as
hypertension, dyslipidaemia, and diabetes. CAD is also the primary risk
factor in the development of heart failure (HF). At the 2nd Asia Pacific
CardioConnect Meeting in Hong Kong sponsored by Menarini, a group of
international and regional experts discussed current strategies for
managing stable CAD and HF and highlighted areas where patient outcomes
may be improved.
At a recent lunch symposium during the 14th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.
anti-inflammatory drugs (NSAIDs) are widely used to treat pain and
inflammation in patients with arthritis, but the vascular effects of some
NSAIDs have cast doubt on whether they can be used in patients at risk for
cardiovascular (CV) disease. At the American Heart Association’s Scientific
Sessions 2016 held recently in New Orleans, Louisiana, US, Professor Steven
Nissen of the Cleveland Clinic in Cleveland, Ohio, US, presented latest data
from the PRECISION (Prospective Randomized Evaluation of Celecoxib Integrated
Safety vs Ibuprofen or Naproxen) trial that evaluated the CV risk and safety
profile of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib vs
Recently, Dr Peter Lin of the Canadian Heart Research Centre spoke on treatment strategies in the management of dyslipidaemia and T2DM at an AstraZeneca-sponsored continuing medical education event. Highlights of his presentations are summarized below.
At the 17th Malaysian Society of Rheumatology/Singapore Society of Rheumatology Workshop, Associate Professor Susanna Proudman, a senior consultant in rheumatology from Australia, shared with the audience on the diagnosis and management of pulmonary arterial hypertension (PAH), with a focus on systemic sclerosis (SSc)-related PAH.
At the recent launch of an exclusive guidebook on vasodilating β-blockers for the treatment of hypertension and chronic heart failure (HF), Professor Athanasios J. Manolis delivered a lecture on why nebivolol is different from the other agents in its class.
During the 8th Diabetes Complications Conference & Grand Rounds 2016, Dr Azani Mohamed Daud talked about the guidelines on the use of ACEIs and ARBs in hypertension, and highlighted their clinical efficacies for hypertension treatment.
Prof. Abdul Rashid, Prof. Martin Strauss, Prof. Alistair Hall, 20161212084416
Hypertension is a leading cause of mortality globally and is of particular concern in the Asia Pacific region where there are more deaths due to poor blood pressure (BP) control than in any other region in the world. At a recent Servier-sponsored satellite symposium held during the ASEAN Federation of Cardiology Congress in Yangon, Myanmar, Professor Abdul Rashid, An Nur Specialist Hospital, Selangor, Malaysia, discussed the challenges associated with managing hypertension in the region. In addition, Professor Martin Strauss, North York General Hospital, Toronto, Canada and Professor Alistair Hall, Leeds General Infirmary, UK, discussed the different effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) on cardiovascular (CV) outcomes, highlighting the additional protection against myocardial infarction (MI) offered by ACE inhibitors such as perindopril.
Individuals with chronic ischaemic heart disease (IHD) and a small left ventricle and thick myocardium demonstrated higher levels of cardiac remodelling as opposed to those with a large ventricle and thin myocardium, contrary to the prevailing understanding, according to the DOPPLER-CIP study.
Chronic kidney disease (CKD), regardless of the stage, appears to have no direct effect on cardiovascular mortality within 180 days and 2 years from digoxin treatment initiation in treatment-naïve patients with non-valvular atrial fibrillation (AF), a Danish cohort study suggests.
The presence of target organ damage (TOD) in hypertension is more likely to result in blood pressure (BP) elevation, independently of the type of measurement (office or ambulatory, central or peripheral), according to a recent study. Central BP, even monitored during 24 hours, is not better correlated with TOD than peripheral BP.
There is no evidence to support the association between neurofibromatosis type 1 and intracranial aneurysms, a new population-based study shows. Moreover, there is no rise in the incidence of aneurysmal subarachnoid haemorrhage in NF1 patients.